arrow
A

Anthea Peters

University of Alberta
H指数:15
被引数:797

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lysosome-Disrupting Agents in Combination with Venetoclax Increase Apoptotic Response in Primary Chronic Lymphocytic Leukemia (CLL) Cells Mediated by Lysosomal Cathepsin D Release and Inhibition of Autophagy

溶酶体破坏剂联合维尼托克可增加溶酶体组织蛋白酶D释放和抑制自噬介导的原发性慢性淋巴细胞白血病 (CLL) 细胞的凋亡反应

CELLS
IF5.2
2024-06-152
OAAI
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (vol 102, pg 1773, 2023)
2023-07-112
OAAI
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

RE-MIND2: 基于复发/难治性弥漫性大b细胞淋巴瘤患者的真实数据,他法他单抗联合来那度胺与polatuzumab维多汀/苯达莫司汀/利妥昔单抗 (pola-br),car-t疗法和来那度胺/利妥昔单抗 (R2) 的疗效比较

2023-05-1213
OAAI
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
2022-05-1819
OAAI
Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia

扩增的抗原经历的CD160 CD8效应T细胞在慢性淋巴细胞白血病中表现出受损的效应子功能

2021-04-3032
OAAI